Ann: Amplia and Garvan Institute Enter Collaboration Agreement, page-10

This isn't exactly ' New ' news folks because you only have to tie back to the recent February Investor update together with recent tweets made by the Garvan Institute by Prof Paul Timpson which confirm a 2021 collaboration between Amplia and the Garvan Institute already was in train.

Of course his Tweet was in reference to two other ' treatments ' and their respective joint collaborations as follows :-

These two treatments, RXC004 (trial led by the Garvan Institute in collaboration with biotech Redx) and sulfasalazine (trial led by UNSW Sydney), have both been shown to target the scar tissue around pancreatic cancers and prevent tumour growth in experimental models.

So one does wonder why it is that they felt it necessary to release a specific ASX announcement for something which should have already been aware by the Markets........ Perhaps it is more to do with some of the ' other ' inferences from the latest Investor Preso released in February 2021.

And so on that point , what I really find Interesting is in reference to Amplia's references in ATX's recent Investor preso is with regards to Defactinib - another FAK inhibitor competitor agent which is owned by Verastem Oncology and who has a current Market Cap of US$398.97 million.

Verastem has also recently entered into a collaboration with Defactnib with Chugai Pharmaceutical Co. Ltd , a Japanese Pharma who is 62% owned by Hoffmann Roche and is valued at US$75 billion. Hoffmann of course is held by Roche Holdings AG which is in turn valued at US $235 billion.

Chungai's shares are up approximately 40% at the time I wrote up my research over 3 weeks ago ) since March 13th 2020 or he beginning of the COVID-19 Pandemic

Interesting as well that Dr frank Neumann who was Verastems Chief Medical Officer for a relatively short tenure and has now taken up a new posting at the Company Kite pharma who is a subsidiary of Gilead Sciences. His new position as Senior Vice President and Global Head of Clinical Development and has been set to lead Kite’s Clinical Development organization across hematological malignancies and solid tumors.

And Investors should also be aware of their ( Gilead's ) recent acquisition of Immunomedics fo US$21 billion which gave them control of cancer treatment hopeful Trodelvy, a first in class antibody drug conjugate.

And there have of course been many many telephone book number type deals initiated and orchestrated by Gilead since their 1990's discovery of Tamiflu which went on to be licensed with Roche for its late phase development and marketing.

So bet folks is that with Chugai , F. JHoffmann - La Roche AG , and Gilead and Immunonmedics ALL seemingly involved in virtually the same area of FAK Inhibitor science and drug discoveries on the same type of cancer tumors , Amplia will not be able to avoid the commercial opportunities and scrutiny which will no doubt be attracted to their efforts.

Exiting times indeed......